MedTrace Logo

Universal CAR-T Cell Therapy for MM

NCT07248176 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-12-01

No results posted yet for this study

Summary

This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.

Conditions

Interventions

DRUG

Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection

The study drug is administered intravenously at a fixed dose within 1-2 days after lymphocyte depletion, and its efficacy and safety are observed.

Sponsors & Collaborators

  • Shanghai Tongji Hospital (Tongji Hospital of Tongji University)

    collaborator UNKNOWN

  • Bioray Laboratories

    lead INDUSTRY

Principal Investigators

  • Ping Li, PhD · 13564181131

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-10
Primary Completion
2027-03-15
Completion
2028-04-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07248176 on ClinicalTrials.gov